What It Means To Hold Moderna Stock In A Crash

The company’s pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

Moderna (MRNA) stock fell 10.8% on July 10th, a sharp move for any holder. This is a biotechnology company with an established respiratory vaccine portfolio and a high-stakes oncology pipeline centered on its individualized therapy, Intismeran. The market is currently weighing management’s forecast for up to 10% revenue growth in 2026 against a looming $950 million litigation payment due in the third quarter and a guided drop in second-quarter revenue to between $50 million and $100 million. This backdrop makes the question of downside risk particularly urgent.

That single-day drop, however, is just a preview. The more important question for any shareholder is how this stock behaves in a true, sustained market shock. History provides a clear, if sobering, pattern. The real test is understanding how far it can fall, how long it can stay down, and whether you can ride that out.

A 50% Drop In The 2022 Inflation Shock

When the broad market stumbles, Moderna has historically fallen harder. Across the seven major shocks it has traded through since 2018, the stock’s average peak-to-trough drop was about 31%, nearly double the S&P 500’s average decline of 17% in the same periods. Its single deepest drawdown was a 50% plunge during the 2022 Inflation Shock & Fed Tightening.

The stock has been hit hardest during shocks driven by interest rates and valuation concerns. To make that concrete, the events in that category were the 2022 Inflation Shock & Fed Tightening and the Summer-Fall 2023 5% Yield Shock. This history of amplified downside is the core risk shareholders carry.

A Median Recovery Of About 6 Months

Surviving the fall is one thing; climbing back is another. For the shocks it has fully recovered from, Moderna took a median of about 6 months to reclaim its prior high. But a quick rebound is not a given. Its slowest full recovery took about 10 months following the 2025 US Tariff Shock.

More importantly, some recoveries have not happened at all. As of today, the stock remains about 71% below its high from before the 2022 Inflation Shock & Fed Tightening. The risk of a long, or even incomplete, recovery is as real as the drop itself.

Every Major Shock Moderna Has Traded Through

Peak-to-trough drawdown in each shock, and how long the stock took to reclaim its pre-shock high. Stock vs. the S&P 500, long-duration bonds, and its sector.

[1] Q4 2018 Fed Policy Error / Growth Scare: Powell’s hawkish comments and trade war fears triggered the worst December since 1931.
[2] 2020 COVID-19 Crash: Pandemic lockdowns caused history’s fastest bear market before massive stimulus drove recovery.
[3] 2022 Inflation Shock & Fed Tightening: 9.1% CPI forced aggressive rate hikes, crushing both stocks and bonds simultaneously.
[4] 2023 SVB Regional Banking Crisis: SVB’s rate-driven bond losses triggered a social-media bank run, seized by FDIC.
[5] Summer-Fall 2023 Five Percent Yield Shock: Strong economic data pushed 10-year yields to 5%, compressing yield-sensitive sector valuations.
[6] 2024 Yen Carry Trade Unwind: BOJ rate hike unwound yen carry trades, briefly crashing tech stocks globally.
[7] 2025 US Tariff Shock: 145% China tariffs crashed equities and the dollar on supply chain disruption fears.

Is Today’s Moderna A Different Company?

Of course, Moderna is not the same company it was during some of those earlier shocks. It now has a strong balance sheet with $7.5 billion in cash and investments, multiple approved products in its respiratory portfolio, and a closely watched late-stage oncology program in Intismeran. These factors suggest a more resilient business.

However, the company is also navigating new challenges. Trailing twelve-month revenue is down, its operating margin is negative, and that $950 million litigation payment represents a significant near-term cash outflow. The company’s valuation is heavily dependent on the success of its clinical pipeline, which carries inherent uncertainty. Given this reliance on future catalysts, the historical pattern of amplified downside in a market shock still appears relevant.

What A 50% Drop Does To Your Portfolio

To make the risk tangible, consider what that deepest 50% drawdown does to a portfolio. On a position sized at 10% of your assets, that single stock would have cut 5% from your entire portfolio’s value. At a 20% position weight, the hit would have been 10%. The question is whether your financial plan can absorb that kind of impact.

The one lever you fully control is not the market’s direction but your own exposure. Disciplined position sizing is the most direct response to this kind of specific stock risk.

Where Else Could A Drop Like This Be Waiting?

You have just seen, in hard numbers, how far Moderna has fallen when markets break, and how long it took to climb back. The natural next question is how much the rest of what you own could fall, and the options market puts a forward number on exactly that: the expected move it prices in for each stock over the year ahead. Our Expected Move screen ranks which S&P 500 names carry the widest priced-in swings, so you can see whether your other holdings are sitting on more downside than you have accounted for.

You Just Saw The Downside. Now Scale It.

The piece above put a number on how far this stock could fall. That math is unsettling on any position – but on one that has quietly become a large share of your net worth, that drawdown is not a scare story, it is your money. And the usual escape, selling to diversify, hands a slice of the gains to the IRS. There is a way to cap that downside and diversify out without the tax hit.